This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Remedy Informatics First And Only Vendor Authorized To Submit Full Suite Of AGNIS-Supported CIBMTR Forms, Launches "Live In Five" Software Deployment Program

"The value of integrating the BMT service line with cell therapy researchers, labs and biobanks is essential to an enterprise seeking to maximize treatment effectiveness and research investment," said Hank Wu, director of translational informatics at Remedy Informatics. "The combination of ComprehensiveBMT and InvestigateCT facilitates multidirectional flow of data, beginning at the patient's initial admission and evaluation and continuing throughout and after the transplantation procedure, allowing researchers to analyze the entire longitudinal view for new findings that can improve outcomes for current and future patients. This is a tangible way to realize the promise of personalized medicine."

"The traditional data process largely fails to use data from one patient to benefit the next, or to utilize clinical data to inform laboratory research and vice versa," said Dewey. "One of our goals is to introduce a new, fully integrated data paradigm for BMT centers and cell therapy labs around the world."

Remedy Informatics will demo both ComprehensiveBMT and InvestigateCT at the 2013 BMT Tandem Meeting held in the Salt Palace in Salt Lake City, Booth #101. Attendees can also participate in Remedy's "Try Then Buy" campaign in order to "test drive" ComprehensiveBMT prior to purchasing the software.

Remedy's cutting-edge BMT research and reporting software serves clients around the world, including the Huntsman Cancer Institute at the University of Utah, Princess Margaret Hospital, The Jewish – Mercy Health BMT Center, and Primary Children's Medical Center in Salt Lake City, UT. Remedy Informatics products were also recently chosen as the technology solution for the European Group for Blood and Marrow Transplantation (EBMT) Registry Upgrade Project.

To request a demo or to learn more about ComprehensiveBMT and how it can benefit your BMT or cancer treatment center, please visit the product page on our website, http://www.remedyinformatics.com/product/comprehensivebmt/.

About Remedy Informatics, Inc.Remedy Informatics, Inc. is the leading provider of clinical registries, medical research software and research informatics products that accelerate translational medicine discoveries from bench to bedside. Remedy offers a wide range of configurable "off the shelf" biomedical informatics products that are built on the powerful Mosaicâ„¢ Platform. Remedy's mission is to tangibly, measurably and permanently improve the effectiveness of life science research and healthcare delivery in the United States and across the globe. For more information visit: www.remedyinformatics.com.

Media Contacts Kristofer Beldin, Remedy Informatics, (801) 870-9407 (cell), kris.beldin@remedyinformatics.com

SOURCE Remedy Informatics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs